These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

608 related items for PubMed ID: 22610723

  • 21. Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder.
    Kollins SH, López FA, Vince BD, Turnbow JM, Farrand K, Lyne A, Wigal SB, Roth T.
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):111-20. PubMed ID: 21476931
    [Abstract] [Full Text] [Related]

  • 22. Evaluation of the current data on guanfacine extended release for the treatment of ADHD in children and adolescents.
    Childress A, Hoo-Cardiel A, Lang P.
    Expert Opin Pharmacother; 2020 Mar; 21(4):417-426. PubMed ID: 31971448
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Guanfacine extended release for the treatment of attention-deficit/hyperactivity disorder in children and adolescents.
    Connor DF, Arnsten AF, Pearson GS, Greco GF.
    Expert Opin Pharmacother; 2014 Aug; 15(11):1601-10. PubMed ID: 24992513
    [Abstract] [Full Text] [Related]

  • 26. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [Abstract] [Full Text] [Related]

  • 27. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
    Swearingen D, Pennick M, Shojaei A, Lyne A, Fiske K.
    Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
    [Abstract] [Full Text] [Related]

  • 28. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder.
    Biederman J, Melmed RD, Patel A, McBurnett K, Konow J, Lyne A, Scherer N, SPD503 Study Group.
    Pediatrics; 2008 Jan; 121(1):e73-84. PubMed ID: 18166547
    [Abstract] [Full Text] [Related]

  • 29. Modeling and simulation of the exposure-response and dropout pattern of guanfacine extended-release in pediatric patients with ADHD.
    Knebel W, Rogers J, Polhamus D, Ermer J, Gastonguay MR.
    J Pharmacokinet Pharmacodyn; 2015 Feb; 42(1):45-65. PubMed ID: 25373474
    [Abstract] [Full Text] [Related]

  • 30. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
    Najib J.
    Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
    [Abstract] [Full Text] [Related]

  • 31. Pharmacokinetics of coadministration of guanfacine extended release and methylphenidate extended release.
    Roesch B, Corcoran M, Haffey M, Stevenson A, Wang P, Purkayastha J, Martin P, Ermer J.
    Drugs R D; 2013 Mar; 13(1):53-61. PubMed ID: 23519656
    [Abstract] [Full Text] [Related]

  • 32. Guanfacine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
    Rizzo R, Martino D.
    Expert Rev Neurother; 2015 Apr; 15(4):347-54. PubMed ID: 25800130
    [Abstract] [Full Text] [Related]

  • 33. Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists.
    Wigal SB, Chae S, Patel A, Steinberg-Epstein R.
    Semin Pediatr Neurol; 2010 Dec; 17(4):230-6. PubMed ID: 21183129
    [Abstract] [Full Text] [Related]

  • 34. Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology.
    Sikirica V, Findling RL, Signorovitch J, Erder MH, Dammerman R, Hodgkins P, Lu M, Xie J, Wu EQ.
    CNS Drugs; 2013 Nov; 27(11):943-53. PubMed ID: 23975660
    [Abstract] [Full Text] [Related]

  • 35. Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison.
    Erder MH, Xie J, Signorovitch JE, Chen KS, Hodgkins P, Lu M, Wu EQ, Sikirica V.
    Appl Health Econ Health Policy; 2012 Nov 01; 10(6):381-95. PubMed ID: 23113551
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study.
    Newcorn JH, Harpin V, Huss M, Lyne A, Sikirica V, Johnson M, Ramos-Quiroga JA, van Stralen J, Dutray B, Sreckovic S, Bloomfield R, Robertson B.
    J Child Psychol Psychiatry; 2016 Jun 01; 57(6):717-28. PubMed ID: 26871297
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.